Ϫ ] increased in a dose-dependent manner, with the peak changes occurring at approximately 2-3 h. Compared with PL, 70 ml BR did not alter the physiological responses to exercise. However, 140 and 280 ml BR reduced the steady-state oxygen (O2) uptake during moderateintensity exercise by 1.7% (P ϭ 0.06) and 3.0% (P Ͻ 0.05), whereas time-to-task failure was extended by 14% and 12% (both P Ͻ 0.05), respectively, compared with PL. The results indicate that whereas plasma [NO 2 Ϫ ] and the O2 cost of moderate-intensity exercise are altered dose dependently with NO 3 Ϫ -rich BR, there is no additional improvement in exercise tolerance after ingesting BR containing 16.8 compared with 8.4 mmol NO 3 Ϫ . These findings have important implications for the use of BR to enhance cardiovascular health and exercise performance in young adults.
NITRIC OXIDE (NO) IS A GASEOUS signaling molecule that modulates human physiological function via its role in, for example, the regulation of blood flow, neurotransmission, immune function, glucose and calcium homeostasis, muscle contractility, and mitochondrial respiration (9, 36) . 1 NO is generated through the oxidation of the amino acid L-arginine in a reaction catalyzed by NO synthase (NOS), with nitrite (NO 2 Ϫ ) and nitrate (NO 3 Ϫ ) being oxidation products of NO (30) . It is now appreciated that under appropriate physiological conditions, NO can also be produced via the reduction of NO 2 Ϫ , a process that may be particularly important in situations where oxygen (O 2 ) availability is low, and/or NOS function is impaired (12) . Interestingly, administration of dietary inorganic NO 3 Ϫ has been shown to increase plasma NO 2 Ϫ concentration ([NO 2 Ϫ ]) and to produce NO-like bioactivity (19, 23, 39) . Up to 25% of ingested NO 3 Ϫ enters the enterosalivary circulation and is concentrated in the saliva, whereupon facultative, anaerobic bacteria in the oral cavity reduce the NO 3 Ϫ to NO 2 Ϫ (30) . When swallowed into the acidic environment of the stomach, some of the NO 2 Ϫ is converted further into NO, whereas the remainder is absorbed to increase circulating plasma [NO 2 Ϫ ]. This NO 2 Ϫ may be reduced further to NO and other reactive nitrogen intermediates, particularly in tissues that may be relatively hypoxic, such as contracting skeletal muscle (30) . We (3, 37) and others (19, 23, 39) have demonstrated that NO 3 Ϫ ingestion, either in the form of NO 3 Ϫ salts or via the consumption of high NO 3 Ϫ vegetable products, such as beetroot juice (BR), reduces resting blood pressure (BP) profoundly and consistently. Consequently, dietary NO 3 Ϫ supplementation has emerged as a potential nutritional agent for the prevention and treatment of hypertension and cardiovascular disease (30) . Webb et al. (39) assessed the effects of acute BR consumption (ϳ23 mmol NO 3 Ϫ ) on plasma [NO 2 
Ϫ
] and BP over 24 h. Plasma [NO 2 Ϫ ] peaked 3 h postingestion, remained close to peak values until 5 h postingestion, and returned to baseline after 24 h (39) . The systolic and diastolic BP and the mean arterial pressure (MAP) were reduced significantly, by ϳ10, ϳ8, and ϳ8 mmHg, respectively, at 2.5-3 h after BR intake. The same research group later reported a dose-dependent increase in plasma [NO 3 Ϫ ] and [NO 2 the above hemodynamic effects (3, 26) . Specifically, we (2, 3, 22) and others (6, 24 -26) have demonstrated that 3-6 days of dietary NO 3 Ϫ supplementation reduces the O 2 cost of moderateintensity exercise and may enhance exercise tolerance in healthy, young adults. It appears that these effects are related to NO 2 Ϫ or NO-mediated enhancements of muscle contractile function (2, 17) and/or mitochondrial efficiency (24) and/or enhanced muscle blood flow, especially to type II fibers (14) . Importantly, a reduction of the O 2 cost of exercise (25, 37) and improved exercise performance (21) has also been reported as early as 2.5 h following a single dose of dietary NO 3 Ϫ , which is consistent with the time required for the peak plasma [NO 2 Ϫ ] to be attained (39) . However, since all exercise-performance studies completed to date with BR have administered approximately 5-8 mmol NO 3 Ϫ , it is unclear whether a dose-response relationship exists between acute NO 3 Ϫ intake and the physiological responses to exercise. The establishment of the doseresponse relationship between NO 3 Ϫ intake and the physiological responses to exercise and the ascertainment of the optimal NO 3 Ϫ dose for enhancing exercise performance are important, given the increasing popularity of BR supplementation in both basic research and applied exercise settings.
Therefore, the purpose of the present study was twofold: firstly, to characterize the plasma [NO 3 Ϫ ] and [NO 2 Ϫ ] pharmacokinetics and the changes in BP after ingestion of three different quantities of NO 3 Ϫ -rich BR; and secondly, to investigate the dose-response relationship between BR/NO 3 Ϫ intake and the physiological responses to exercise. In two separate experiments, we administered a BR concentrate that enabled a substantial NO 3 Ϫ load to be ingested quickly and easily. We investigated: 1) the influence of acute NO 3 Ϫ doses of 4.2, 8.4, and 16.8 mmol consumed in 70, 140, and 280 ml concentrated BR on plasma [NO 3 Ϫ ] and [NO 2 
] and BP over a 24-h period; and 2) the physiological responses to step transitions to moderate-and severe-intensity exercise, 2.5 h postingestion of the same NO 3 Ϫ doses. We hypothesized that the effects of dietary inorganic NO 3 Ϫ on plasma [ ], BP, the O 2 cost of moderate-intensity exercise, and exercise tolerance (assessed as the time-to-task failure) during severe-intensity exercise would be dose dependent.
METHODS
The study was conducted in two phases [study 1 (S1), pharmacokinetics; and S2, dose response], with the results generated in S1 used to inform the experimental design in S2. There was distinct subject recruitment for each experiment. Ten healthy, recreationally active men volunteered for each experiment [mean Ϯ SD: S 1, age 23 Ϯ 5 yr, height 1.79 Ϯ 0.07 m, body mass (BM) 79 Ϯ 9 kg; S2, age 22 Ϯ 5 yr, height 1.77 Ϯ 0.05 m, BM 74 Ϯ 8 kg]. None of the subjects in S1 and S2 was a tobacco smoker or user of dietary supplements. All subjects recruited for S2 were fully familiar with laboratory exercise-testing procedures, having participated previously in studies using cycle ergometry in our laboratory. The procedures used in S 1 and S2 were granted full ethics approval by the Institutional Research Ethics Committee. All subjects gave their written, informed consent to participate after the experimental procedures, associated risks, and potential benefits of participation had been explained in detail.
All subjects in S 1 and S2 were instructed to keep a food and physical-activity diary in the 24 h preceding their first laboratory visit and to replicate food consumption and physical activity in the 24 h preceding subsequent visits. The subjects were required to arrive at the laboratory in a rested and fully hydrated state, following an overnight fast, and to avoid strenuous activity in the 24 h preceding each testing session. Subjects were instructed to refrain from caffeine and alcohol-containing drinks for 6 and 24 h before each laboratory visit, respectively, and to abstain from using antibacterial mouthwash and chewing gum throughout the study, because these are known to eradicate the oral bacteria that are necessary for the conversion of NO 3 Ϫ to NO 2 Ϫ (16).
S 1: Pharmacokinetics and Pharmacodynamics
Procedures. All subjects reported to the laboratory on four separate occasions over a period of 3 wk. Upon arrival to the laboratory, resting BP was measured, and a venous blood sample was obtained for the measurement of plasma [NO 2 Ϫ ] and [NO 3 Ϫ ]. Subjects then consumed an acute dose of 70, 140, or 280 ml NO 3 Ϫ -rich BR (organic BR containing ϳ4.2, ϳ8.4, or ϳ16.8 mmol NO 3 Ϫ , respectively; Beet It; James White Drinks, Ipswich, UK) or 140 ml water [control (CON)], in addition to a standardized breakfast (72 g porridge oats with 180 ml semiskimmed milk). BP was measured, and a venous blood sample was obtained, 1, 2, 4, 8, 12, and 24 h postingestion. For each 24-h period of data collection, subjects were provided with a standardized, low NO 3 Ϫ diet. The quantity and timing of food and drink intake were recorded on visit 1 and replicated in subsequent visits. A washout period of at least 3 days separated the laboratory visits.
Measurements. The BP of the brachial artery was measured using an automated sphygmomanometer (Dinamap Pro; GE Medical Systems, Tampa, FL), with the subjects in a seated position. After arrival at the laboratory and following 10 min of rest in an isolated room, four measurements were recorded, and the mean of the final three measurements was used for data analysis.
Venous blood samples were drawn into lithium-heparin tubes (7.5 ml Monovette lithium heparin; Sarstedt, Leicester, UK). Samples were centrifuged at 4,000 rpm and 4°C for 7 min, within 1 min of collection. Plasma was subsequently extracted and immediately frozen at Ϫ80°C for later analysis of [ Ϫ ] of the undiluted (nondeproteinized) plasma was determined by its reduction to NO in the presence of glacial acetic acid and 4% (w/v) aqueous sodium iodide. The spectral emission of electronically excited nitrogen dioxide product, from the NO reaction with ozone, was detected by a thermoelectrically cooled, red-sensitive photomultiplier tube, housed in a Sievers gas-phase chemiluminescence NO analyzer (NOA; Sievers NOA 280i; Analytix, Durham, UK). The [NO 2 Ϫ ] was determined by plotting signal (mV) area against a calibration plot of 100 nM-1 M sodium NO 2 Ϫ . Before determination of [NO 3 Ϫ ], samples were deproteinized using zinc sulfate (ZnSO4)/sodium hydroxide (NaOH) precipitation. Aqueous ZnSO4 [400 l 10% (w/v)] and 400 l 0.5 M NaOH were added to 200 l of sample and vortexed for 30 s before being left to stand at room temperature for 15 min. Thereafter, samples were centrifuged at 4,000 rpm for 5 min, and the supernatant was removed for subsequent analysis. The [NO 3 Ϫ ] of the deproteinized plasma sample was determined by its reduction to NO in the presence of 0.8% (w/v) vanadium trichloride in 1 M HCl. The production of NO was detected using the chemiluminescence NOA, as described above.
To determine more precisely the time-to-peak plasma [NO 2 Ϫ ] following NO 3 Ϫ ingestion, a one-compartment model with first-order absorption and elimination kinetics was used, as described in the following equation
where Y represents fraction absorbed; X represents time; and, Ka and Ke represent the first-order absorption and elimination rate constants, respectively.
Statistical analysis. Protocol. Subjects were required to report to the laboratory on seven separate occasions, over a 4-to 5-wk period. During the first visit to the laboratory, subjects completed a ramp incremental exercise test for determination of peak O 2 uptake (V O2 peak) and gas-exchange threshold (GET). All tests were performed on an electronically braked cycle ergometer (Lode Excalibur Sport, Groningen, The Netherlands). Initially, each subject completed 3 min of "unloaded" baseline cycling; then, the work rate was increased by 30 W/min until the subject was unable to continue. The subjects cycled at a self-selected pedal rate (70 -90 rpm), and this pedal rate along with the saddle and handlebar height and configuration were recorded and reproduced in subsequent tests. The breath-by-breath pulmonary gas-exchange data were collected continuously during the incremental tests and averaged over consecutive 10-s periods. V O2 peak was taken as the highest 30-s mean value attained before the subject's volitional exhaustion. The GET was determined as described previously (3, 37) . The work rates that would require 80% of the GET (moderate-intensity exercise) and 75% of the difference between the power output at GET and V O2 peak plus the power output at GET, i.e., severe-intensity exercise (⌬) were subsequently calculated.
On test days, subjects arrived at the laboratory at ϳ8 AM. A venous blood sample was drawn for measurement of plasma [ Ϫ ; Beet It). All BR and PL doses were administered using a randomized, double-blind crossover design. Subjects were asked to consume the beverage within a 5-min period and, after doing so, were served a standardized breakfast (72 g porridge with 180 ml semiskimmed milk). A washout period of at least 72 h separated each visit.
After ingestion of the beverage, subjects were given a period of 2.5 h, during which they were allowed to leave the laboratory but were asked to refrain from strenuous physical activity. Subjects were also asked to fast during this time, although water was permitted ad libitum. Following this 2.5-h period, a second venous blood sample was drawn for measurement of plasma [NO 2 Ϫ ] and [NO 3 Ϫ ]. Subjects then completed "step" exercise tests, from a 20-W baseline to moderate-intensity (93 Ϯ 11 W) and severe-intensity (258 Ϯ 23 W) work rates for the determination of pulmonary V O2 dynamics. On each visit, subjects completed two, 5-min bouts of moderate-intensity exercise and one bout of severe-intensity exercise that was continued until task failure as a measure of exercise tolerance. All bouts of exercise on each day were separated by 5 min of passive rest. The time-to-task failure was recorded when the pedal rate fell by Ͼ10 rpm below the self-selected pedal rate. In the severe-intensity bouts, the subjects were verbally encouraged to continue for as long as possible.
Measurements. During all exercise tests, pulmonary gas exchange and ventilation were measured breath by breath, with subjects wearing a nose clip and breathing through a low dead-space (90 ml), lowresistance (0.75 mmHg1 Ϫ1 ·s Ϫ1 at 15 l/s) mouthpiece and impeller turbine assembly (Jaeger Triple-V; Jaeger GmbH, Hoechberg, Germany). The inspired and expired gas volume and gas concentration signals were sampled continuously at 100 Hz-the latter using paramagnetic (O2) and infrared [carbon dioxide (CO2)] analyzers (Oxycon Pro; Jaeger GmbH) via a capillary line connected to the mouthpiece. These analyzers were calibrated before each test with gases of known concentration, and the turbine volume transducer was calibrated using a 3-liter syringe (Hans Rudolph, Kansas City, MO). The volume and concentration signals were time aligned by accounting for the delay in capillary gas transit and analyzer rise time relative to volume signal. O 2 uptake, CO2 output, and minute ventilation were calculated using a standard formula and displayed breath by breath. Heart rate (HR) was measured using short-range radiotelemetry (model RS400; Polar Electro Oy, Kempele, Finland).
Capillary blood samples were collected from the fingertip into a capillary tube during the baseline, preceding each step transition in work rate; during the final 30 s of each moderate-intensity exercise bout; and following exhaustion in the severe-intensity exercise bout. These samples were analyzed immediately to determine blood lactate concentration ([lactate]; model YSI 1500; Yellow Springs Instrument, Yellow Springs, OH). Venous blood samples were treated and analyzed as described in S 1.
The breath-by-breath data from each exercise test were linearly interpolated to provide second-by-second values, and the two identical, moderate-intensity repetitions performed on each visit were time aligned to the start of exercise and ensemble averaged. Baseline V O2 (V O2baseline), expired CO2 at baseline (V CO2baseline), and respiratory exchange ratio (RER) at baseline were defined as the mean values measured over the final 90 s of baseline pedaling. The end-exercise V O2, V CO2, and RER were defined as the mean values measured over the final 30 s of exercise. The amplitude of the V O2 response was calculated by subtracting V O2baseline from V O2 at the end of exercise. Subsequently, the functional gain of the entire response was calculated by dividing the V O2 amplitude by the change (⌬) in work rate. The amplitude of the V O2 slow component during the severe-intensity exercise bout was estimated by subtracting the mean V O2 at 2 min from the mean V O2 at 6 min.
Statistical analysis. Two-way repeated-measures ANOVA was used to assess the difference in pulmonary gas-exchange variables, blood [lactate], and HR across dose (70, 140, and 280 ml) and treatment (PL and BR). Differences in pre-and postplasma [NO 2 Ϫ ] and [NO 3 Ϫ ] were assessed separately in PL and BR, across dose and time (pre and post) using two-way repeated-measures ANOVAs. Significant main and interaction effects were analyzed further using simple contrasts. Statistical significance was accepted at P Ͻ 0.05. Results are presented as mean Ϯ SD unless stated otherwise.
RESULTS
Ingestion of BR was tolerated well by all subjects in S 1 and S 2 . Subjects did, however, report beeturia (red urine) and red stools, consistent with previous studies (3, 39) . The absolute Fig. 3, A and B The V CO 2baseline , measured over the last 90 s of 20 W pedaling, and the end-exercise V CO 2 , measured over the last 30 s of exercise, were affected by dose (P Ͻ 0.05 for both) but not condition (P Ͼ 0.05 for both; Table 1 ). Follow-up tests revealed that V CO 2baseline was increased significantly, as the volume of supplement ingested increased (P Ͻ 0.05), irrespective of the condition (i.e., PL or BR). Specifically, V CO 2baseline was increased by ϳ7% and ϳ5% following consumption of 280 ml of supplement relative to 70 and 140 ml, respectively (P Ͻ 0.05 for both). There were no significant differences in V CO 2 between the ingestion of 70 and 140 ml of supplement (P Ͼ 0.05). Furthermore, post hoc analysis revealed that the end-exercise V CO 2 was significantly higher following ingestion of both 140 and 280 ml of supplement relative to 70 ml (P Ͻ 0.01 for both). There was, however, no significant difference in end-exercise V CO 2 between ingestion of 140 and 280 ml of supplement (P Ͼ 0.05).
Baseline and end-exercise RER were affected by dose (P Ͻ 0.05 for both) but not condition (P Ͼ 0.05). The follow-up tests indicated that RER increased as the volume of supplement ingested increased (P Ͻ 0.05; Table 1 ). Specifically, RER at baseline was increased by ϳ5% and ϳ4%, following consumption of 280 ml of supplement relative to 70 and 140 ml, respectively (P Ͻ 0.05 for both). Although there was no significant interaction effect or main effect by condition, baseline RER tended to be higher (by ϳ3%) following administration of 16.8 mmol NO 3 Ϫ compared with the respective PL (P ϭ 0.08). End-exercise RER was increased significantly by ϳ4% and ϳ3%, following consumption of 280 ml compared with 70 and 140 ml of supplement, respectively (P Ͻ 0.05 for both). In addition, the ingestion of 140 ml increased end-exercise RER compared with ingestion of 70 ml of supplement (P Ͻ 0.05). The baseline, end-exercise, and change in blood [lactate] and HR were not altered significantly by dose or condition (Table 2 ; P Ͼ 0.05).
Severe-intensity exercise. The pulmonary gas exchange and ventilatory responses to severe-intensity exercise across all doses and conditions are summarized in Table 1 . In contrast to the effects observed for moderate-intensity exercise, the V O 2 and V CO 2 measured at baseline and at task failure were not altered by dose or treatment (all P Ͼ 0.05). Moreover, neither the dose nor the treatment altered the V O 2 slow component amplitude (P Ͼ 0.05 for both). There was a trend toward significant main effects by dose (P ϭ 0.09) and treatment (P ϭ 0.08) but no interaction effect on RER at baseline (P Ͼ 0.05). Follow-up tests revealed that there was a trend toward significant increases in RER at baseline by ϳ4% and ϳ3% following consumption of 280 ml of supplement compared with the consumption of 70 (P ϭ 0.06) or 140 ml (P ϭ 0.08) of supplement, respectively. RER, at task failure, was not altered by dose or treatment (P Ͼ 0.05). The baseline, end-exercise, and change in blood [lactate] and HR were not altered significantly by dose or condition (Table 2 ; P Ͼ 0.05).
There was a significant main effect by condition (P Ͻ 0.05) but not dose (P Ͼ 0.05) on time-to-task failure (Table 1 and Ϫ was correlated significantly with the change in time-to-task failure (r ϭ 0.55; P Ͻ 0.05). There was no significant difference in time-to-task failure among 4.2, 8.4, and 16.8 mmol BR (all P Ͼ 0.05) or among PL70, PL140, and PL280 (P Ͼ 0.05).
In terms of positive changes in time-to-task failure, there were three "nonresponders" in the 4.2-mmol condition, two in the 8.4-mmol condition, and one in the 16.8-mmol condition. Individual subjects who did not respond at lower doses did respond at higher doses. The increase in plasma [NO 2 Ϫ ] from baseline to pre-exercise for the nonresponders was similar to the other subjects who did respond. For example, the three nonresponders at the lowest NO 3 Ϫ dose had an increase in plasma [ , administered in the form of BR, resulted in peak reductions of systolic BP of ϳ5, ϳ10, and ϳ9 mmHg and peak reductions of MAP of ϳ2, ϳ5, and ϳ5 mmHg, respectively. Moreover, BR ingestion resulted in a similar "threshold" effect on diastolic BP, with peak reductions of ϳ3 and ϳ4 mmHg following administration of 8.4 and 16.8 mmol NO 3 Ϫ ; however, ingestion of 4.2 mmol NO 3 Ϫ did not reduce diastolic BP significantly. These reductions in BP are similar to those reported by Kapil et al. (19) following acute administration of KNO 3 , except that Kapil et al. (19) reported a dose-dependent reduction in BP up to 24 mmol KNO 3 . The reason for this discrepancy between studies is unclear. Interestingly, compared with Kapil et al. (19) , who reported 6 mmHg and 9 mmHg reductions in systolic BP following the consumption of 12 mmol and 24 mmol KNO 3 , respectively, we observed larger reductions in BP following the consumption of BR (e.g., a peak reduction of 10 mmHg in systolic BP with 8. The results of the present study suggest that BR (and presumably other NO 3 Ϫ -rich vegetable) consumption can provide a natural approach to maintaining or improving BP and Ϫ -depleted BR (PL; black bars). End-exercise V O2 during moderateintensity exercise was reduced significantly following the ingestion of 280 ml BR. Time-to-task failure during severe-intensity exercise was extended after consumption of 140 ml BR with no further increase following 280 ml BR. *Significant difference from PL (P Ͻ 0.05). vascular health in young adults. The reductions in BP, evident in the present study, are noteworthy. For example, it has been suggested that lowering systolic BP by 10 mmHg may reduce the risk of ischemic heart disease by ϳ25% and the risk of stroke by ϳ35% (27) (28) (29) 31) . The beneficial hemodynamic effects of NO 3 Ϫ supplementation are thought to be due to the reduction of NO 3 Ϫ to NO 2 Ϫ and then to NO within the blood vessel (13) , resulting in arterial dilatation and a reduced peripheral resistance (39). However, it is possible that NO 2 Ϫ itself may also exert a direct effect on the vascular system, independent of NO formation (1) . There are several advantages to using inorganic rather than organic NO 3 Ϫ for the prevention or treatment of hypertension (33) . These include a slow and controlled increase in plasma [NO 2 Ϫ ] following inorganic NO 3 Ϫ intake (due to NO 3 Ϫ uptake into the enterosalivary circulation) compared with the more abrupt changes in plasma [NO 2 Ϫ ] (perhaps to toxic levels) and BP, which can occur with organic NO 3 Ϫ administration (33) . Moreover, unlike the chronic administration of organic NO 3 Ϫ , inorganic NO 3 Ϫ does not appear to lead to the development of tolerance (37) and endothelial dysfunction (33).
S 2 : Dose Response
The results of S 2 confirm that concentrated BR consumption causes a dose-dependent increase in plasma [NO 3 Ϫ ] by 334%, 778%, and 1,556% and plasma [NO 2 Ϫ ] by 121%, 218%, and 338%, 2. ] reported in S 2 are somewhat lower than those reported at 2-4 h postingestion of BR in S 1 . Given that there was distinct subject recruitment for S 1 and S 2 , it is likely that this discrepancy is due to individual variations in the pharmacokinetic response to BR consumption. For example, when the individual plasma [NO 2 Ϫ ] responses to the ingestion of 16.8 mmol NO 3 Ϫ in S 1 are considered, peak concentrations ranged from 493 to 1,523 nM, and the time-to-peak concentration ranged from 130 to 367 min. The cause of this wide interindividual variability in the response of plasma [NO 2 Ϫ ] to NO 3 Ϫ ingestion is unclear, although it may depend, in part, on salivary flow rate; also, it is known that the reduction of NO 3 Ϫ to NO 2 Ϫ is highly dependent on the activity of oral bacteria (16, 39) . Another consideration is that the absolute NO 3 Ϫ doses administered in the present study (4.2, 8.4 , and 16.8 mmol in 1, 2, and 4 BR shots, respectively) resulted in somewhat different NO 3 Ϫ doses when expressed relative to BM (0.05-0.07, 0.09 -0.13, and 0.19 -0.25 mmol NO 3 Ϫ /kg BM, respectively).
Dose Response: Moderate-Intensity Exercise
This is the first study to assess the acute dose-dependent physiological responses to exercise following dietary NO 3 Ϫ supplementation in humans. We assessed the acute response to three different doses of BR at 2.5 h postingestion, based on the significant dose-dependent elevation in plasma [NO 2 Ϫ ] observed at 2-3 h postingestion in S 1 (Fig. 1B) (37) but is smaller than the 6% reduction reported 1 h postingestion of 0.033 mmol/kg BM sodium nitrate (25) . In contrast to acute ingestion, longer-term BR supplementation (3-6 days at approximately 5-7 mmol NO 3 Ϫ /day) resulted in an approximate 5-7% reduction in steady-state V O 2 during moderate-intensity cycling (3, 26) and running (22) .
Previous studies have indicated that the lowering of submaximal exercise V O 2 , following dietary NO 3 Ϫ supplementation, may result from improved mitochondrial efficiency (25) and/or a reduction in the ATP cost of muscle force production (4) . Alterations in protein expression have been proposed as the mechanistic basis for these effects (17, 24) ; however, it is unlikely that these alterations occur quickly enough to explain the effects observed so soon (1-2.5 h) after NO 3 Ϫ ingestion (25, 37) . Alternatively, NO may acutely and reversibly impact protein function through post-translational protein modifications. For instance, S-nitrosation of adenine nucleotide translocase or other mitochondrial or calcium-handling proteins (35) may contribute to the acute reduction in O 2 cost of exercise following BR ingestion. The mechanistic basis for the acute changes in the O 2 cost of exercise following BR ingestion warrants further investigation.
An interesting observation was the dose-dependent increase in baseline and end-exercise V CO 2 , irrespective of condition (i.e., PL or BR). This small but significant rise in V CO 2 led to a dose-dependent increase in RER that was more pronounced during baseline cycling compared with the exercising steadystate. An elevation in RER is indicative of a shift in substrate use toward a relatively greater reliance on carbohydrate and is likely due to the sugar content of the concentrated BR and PL beverages (ϳ16 g/70 ml).
Dose Response: Severe-Intensity Exercise
A novel finding of the present study was that 8.4 and 16.8 mmol NO 3 Ϫ , but not 4.2 mmol NO 3 Ϫ , administered acutely in the form of concentrated BR, significantly improved the timeto-task failure by 14% and 12%, respectively, during severeintensity exercise. These findings are similar to the 14 -16% improvement in exercise tolerance reported previously following 5-6 days of BR supplementation at a lower dose (5-6 mmol NO 3 Ϫ ) (3, 22) . Although the mechanism(s) responsible for the ergogenic potential of NO 3 Ϫ supplementation remain uncertain, they are believed to be mediated via a biochemical reduction of ingested NO 3 Ϫ to biologically active NO 2 Ϫ and NO (4) . NO has been linked to the efficiency of aerobic respiration (9) and the regulation of muscle contraction (35) . Indeed, both more efficient mitochondrial oxidative phosphorylation, via a reduced proton leak across the inner mitochondrial membrane (24) and a reduced ATP and phosphocreatine cost of muscle force production (2, 15) , has been reported following dietary NO 3 Ϫ supplementation. In addition, recent evidence suggests that BR supplementation results in a marked increase in muscle blood flow during exercise in rats, with the blood flow preferentially distributed to muscle groups that principally contain type II fibers, which are recruited during severe-intensity exercise (14) . Furthermore, NO 3 Ϫ supplementation has been shown to increase muscle force production in mice via modulation of intracellular calcium ion (Ca 2ϩ ) handling in fasttwitch fibers (17) . It is possible that these mechanisms operate simultaneously and/or synergistically, resulting in enhanced exercise tolerance. It is, however, important to note that the studies that demonstrated effects of NO 3 Ϫ supplementation on muscle metabolic and vascular control mechanisms (2, 14, 17, 24) used chronic, rather than acute, NO 3 Ϫ supplementation protocols. On the other hand, Cosby et al. (10) reported acutely increased blood flow to exercising forearm muscle following infusion of NO 2 Ϫ into the brachial artery. It is possible that the improved time-to-task failure that we observed with 8.4 and 16.8 mmol NO 3 Ϫ was related to improved blood flow to muscle or to a NO-mediated enhancement of local matching of O 2 delivery to metabolic rate. This would be consistent with reports that BR supplementation results in a preferential distribution of blood flow to type II fibers (14) and improves oxidative function in hypoxic muscle (38) . The lack of a further improvement in time-to-task failure with 16.8 mmol compared to 8.4 mmol NO 3 Ϫ mirrors the lack of an additional effect of consuming the higher NO 3 Ϫ dose on the peak reduction in BP that we observed in S 1 , suggesting that the acute effects of BR ingestion on exercise tolerance may be related, at least in part, to effects on the vasculature. Further studies are needed to establish which mechanisms may be responsible for the ergogenic potential of NO 3 Ϫ , at least at high doses, as early as 2.5 h after ingestion of BR.
The results of the present study indicate a dose-dependent effect of BR supplementation on exercise tolerance up to 8.4 mmol, with no further benefit (indeed a small reduction in exercise tolerance compared with 8.4 mmol) following ingestion of 16.8 mmol NO 3 Ϫ . A possible explanation for this threshold might be a NO-dependent reduction in skeletal muscle force via modulation of excitation-contraction coupling. It has been reported that the opening of the Ca 2ϩ release channels of the sarcoplasmic reticulum (SR) is inhibited by NO (32, 35) and highly related to NO availability (35) . In addition, Ca 2ϩ transport (35) , SR Ca 2ϩ -ATPase activity (18) , and cytochrome c-oxidase inhibition (9) may be influenced by NO and contribute to a dose-dependent modulation of excitation-contraction coupling. Therefore, whereas an increase in NO bioavailability may result in a more efficient mitochondrial function (24) and changes to type II fiber contractility (17) and blood flow (14) , it is possible that these positive effects may be offset by impairments of mitochondrial or contractile function at higher NO levels that might promote nitrative stress. These suggestions are naturally speculative and await further investigation.
The improvements in time-to-task failure during severeintensity exercise, following ingestion of 8.4 and 16.8 mmol NO 3 Ϫ in the present study, were evident without any significant changes in the V O 2 response to exercise. Neither the amplitude of the V O 2 slow component nor the end-exercise V O 2 was influenced by acute ingestion of up to 16.8 mmol NO 3
Ϫ
. This finding is consistent with some (20) but not all previous reports (3, 22) . For example, Bailey et al. (3) reported that 3 days of BR supplementation reduced the V O 2 slow-component amplitude by 23% and improved exercise tolerance by ϳ16%. In contrast, Kelly et al. (20) reported that 3 days of BR supplementation improved exercise tolerance at three different severe intensities by 12-17%, without any accompanying changes in the V O 2 response. We found no difference in end-exercise V O 2 between BR and PL at any dose. In the severe exerciseintensity domain, the V O 2 at the point of volitional exhaustion would be expected to equal the maximum V O 2 (V O 2 max ) (11). Our results are therefore consistent with some (3, 37) but not all (5, 25) previous studies that indicate that NO 3 Ϫ supplementation does not reduce V O 2 max . Interestingly, there was a disconnect between the effects of BR on steady-state V O 2 during moderate-intensity exercise (where the greatest reduction occurred at the highest dose of NO 3 Ϫ ) and the effects of BR on exercise tolerance (where the increased time-to-task failure was similar with 8.4 and 16.8 mmol NO 3 Ϫ ). Collectively, these results appear to indicate that the effects of BR on severeintensity exercise performance may be independent from the effects of BR on the O 2 cost of submaximal exercise.
It should be noted that while an approximate 12-14% extension of time-to-task failure during severe-intensity, constant work-rate exercise, following acute BR ingestion, may appear impressive, this is likely to translate into no more than a 1-2% reduction in the time to complete a given distance, for example, during a short endurance time-trial (TT) event (34) . This is similar to the magnitude of improvement in performance reported previously for 4 km and 16.1 km TT after acute BR ingestion (21) and for 10 km TT following 6 days of BR supplementation (6) . A 1% improvement in performance is highly meaningful in elite sport. For example, it could improve 1,500-m running performance by ϳ2 s or 3,000-m running performance by approximately 4 -5 s in international standard athletes. It remains unclear, however, whether elite athletes may confer a performance benefit from NO 3 Ϫ supplementation. Several studies now indicate that at least when NO 3 Ϫ is ingested acutely, TT performance is not enhanced in highly trained endurance athletes (7, 8, 40) . This may be related to factors such as greater NOS activity, better muscle oxygenation and mitochondrial efficiency, and a lower fraction of type II fibers in the muscles of highly endurance trained compared with moderately trained subjects (40) . It is possible that the doseresponse relationship between NO 3 Ϫ ingestion and changes in exercise performance are different in elite compared with sub-elite subjects, such that larger NO 3 Ϫ doses and/or longer supplementation periods may be required to elicit improved exercise performance. The significant correlation between the change in plasma [NO 2 Ϫ ] and the change in time-to-task failure indicates that the dietary NO 3 Ϫ intervention must be sufficient to increase plasma [NO 2 Ϫ ] if performance is to be improved. In this regard, an important consideration may be the timing of supplementation relative to the start of exercise. The present study shows that on average, plasma [NO 2 Ϫ ] takes longer to peak when larger doses of NO 3 Ϫ are imbibed. However, there are appreciable interindividual differences in the speed with which ingested NO 3 Ϫ is reduced to NO 2 Ϫ , which may preclude any more specific advice other than to consume NO 3 Ϫ some 2-3 h before the start of exercise.
It has been suggested previously that there may be "responders" and nonresponders to dietary NO 3 Ϫ supplementation (40), and there was evidence of this in the present study. Interestingly, the number of nonresponders (in terms of exercise capacity) decreased as the dose ingested increased. For example, there were three nonresponders in the 4.2-mmol condition, two in the 8.4-mmol condition, and one in the 16.8-mmol condition. Two of the subjects who did not respond at the lowest dose did respond to the larger doses, and one subject who did not respond following administration of 4.2 or 8.4 mmol did respond to the 16.8-mmol dose. This suggests that some individuals will require a larger acute dose than others to elicit any positive effects on exercise capacity from dietary NO 3 Ϫ ingestion. Unlike in our previous study (40) , the increase in plasma [NO 2 Ϫ ] from baseline to pre-exercise for the nonresponders was not smaller than that measured in other subjects who did respond, and the nonresponders did not have particularly high baseline plasma [ . Although the mechanistic bases for the reduction in the O 2 cost of submaximal exercise and enhancements in exercise tolerance following acute dietary BR remain unclear, these results provide important, practical information that may underpin the potential use of BR/NO 3 Ϫ supplementation for improving cardiovascular health in the general population and for enhancing exercise performance in athletes.
